Affimed NV has inked a deal with Roche's Genentech unit which could be worth billions of dollars and make the German biotech a major player in the next wave of immuno-oncology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?